|
| |
New Scientific Review Shows That Zolmitriptan ('Zomig(TM)') Nasal Spray Provided Efficacious Relief From Cluster Headache
Sep 08, 2008 -- Results from a new pooled data analysis presented at the European Headache and Migraine Trust International Congress (EHMTIC) 2008 today show that zolmitriptan ('Zomig') nasal spray provided fast and efficacious relief in the treatment of episodic and chronic cluster headache.
|
Biovail Receives Canadian Approval For Ralivia™ For The Treatment Of Moderately Severe Pain
Sep 08, 2008 -- Biovail Corporation (NYSE:BVF)(TSX:BVF) announced that it has received an expanded indication for once-daily Ralivia™ - to include the treatment of moderately severe pain in addition to moderate pain - from the Therapeutic Products Directorate (TPD) in Canada. Ralivia™ is now indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more.
|
NovaDel Announces Data From Pilot Efficacy Study Comparing Sumatriptan Oral Spray To Imitrex(R) Tablets
Sep 06, 2008 -- NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations for a broad range of marketed treatments, today announced data from its Pilot Efficacy Study of its Oral Spray formulation of sumatriptan (Sumatriptan OS) compared to sumatriptan tablets, marketed as Imitrex®/Imigran®, the leading triptan indicated for the treatment of migraine headaches.
|
Amgen And Wyeth Statement On The FDA Safety Announcement Regarding Tumor Necrosis Factor (TNF) Blockers
Sep 06, 2008 -- Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers [marketed as Remicade® (infliximab), Enbrel® (etanercept), Humira® (adalimumab) and Cimzia® (certolizumab pegol)].
|
Pain Killers And Stimulants Less Risky Than Cocaine, More Risky Than Marijuana, According To College Freshmen
Sep 06, 2008 -- First year college students believe that occasional nonmedical use of prescription pain killers and stimulants is less risky than cocaine, but more risky than marijuana or consuming five or more alcoholic beverages every weekend, according to a new study published in the September issue of Prevention Science, the peer-reviewed journal of the Society for Prevention Research.
|
Plexxikon Initiates Phase 1 Trial for PLX5568 - First-in-Class Drug For The Treatment of Pain and Polycystic Kidney Disease
Sep 05, 2008 -- Plexxikon Inc. announced that it has initiated a Phase 1 human clinical trial for PLX5568, a novel kinase inhibitor targeted for the treatment of at least two major indications with unmet medical needs: pain as well as polycystic kidney disease (PKD). PLX5568 has demonstrated robust preclinical efficacy in multiple pain models, including neuropathic pain as well as acute and inflammatory pain. In addition, PLX5568 has demonstrated compelling efficacy in multiple preclinical models of PKD.
|
What A Sleep Study Can Reveal About Fibromyalgia
Sep 05, 2008 -- Research engineers and sleep medicine specialists from two Michigan universities have joined technical and clinical hands to put innovative quantitative analysis, signal-processing technology and computer algorithms to work in the sleep lab.
|
Half Of Adults At Risk For Painful Knee Arthritis
Sep 05, 2008 -- A landmark government study suggests nearly one in two people (46%) will develop painful knee osteoarthritis over their lifetime, with the highest risk among those who are obese. According to the Arthritis Foundation, the study underscores the immediate need for the public to understand what they can do to reduce the tremendous pain, disability and cost associated with arthritis. Arthritis is exploding in an aging population of U.S. baby boomers. Nearly one in five U.S.
|
FDA Approvals For Dexamethasone Sodium Phosphate Injection USP, 4 Mg (Base)/mL And Dexamethasone Sodium Phosphate Injection USP, 10 Mg (Base)/mL
Sep 04, 2008 -- Akorn-Strides, LLC announced the approval of two ANDAs for Dexamethasone Sodium Phosphate Injection USP, 4 mg (base)/mL in 1mL, 5 mL, and 30 mL vials, and Dexamethasone Sodium Phosphate Injection USP, 10 mg (base)/mL in 10 mL vials. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR)(BSE: 532531).
|
Experts Advise Parents Ibuprofen Is Best To Reduce Fever In Children
Sep 03, 2008 -- A new study(1) published on BMJ.com suggests that giving a child a product, such as Nurofen for Children , can reduce their fever for longer. Whilst fever is a normal part of childhood illness, it affects around 70% of pre-school children every year.
|
|